Primary prevention of sudden cardiac death: Can we afford the cost of cardioverter-defibrillators? Data from the Search-MI Registry-Italian Sub-study

PACE - Pacing and Clinical Electrophysiology

Volumn 29, Issue SUPPL. 2, 2006, Pages

  Boriani, Giuseppe ^a   Biffi, Mauro ^a   Russo, Maurizio ^b   Lunati, Maurizio ^c   Botto, Gianluca ^d   Proclemer, Alessandro ^e   Vergara, Giuseppe ^f   Rahue, Werner ^g   Martignani, Cristian ^a   Ricci, Renato ^b   Santini, Massimo ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAN FILIPPO NERI HOSPITAL   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d SANT ANNA HOSPITAL   (Italy)

^e SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^f Civile Hospital   (Italy)

^g S Maurizio Hospital   (Italy)

Author keywords

Cardioverter defibrillator; Cost; Cost effectiveness; Primary prevention; Sudden cardiac death

Indexed keywords

ARTICLE; CARDIOVERSION; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DEFIBRILLATION; DEFIBRILLATOR; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART DEATH; HEART LEFT VENTRICLE FAILURE; HUMAN; IMPLANT REGISTRY; ITALY; PATIENT SELECTION; PRIMARY PREVENTION; SUDDEN DEATH;

AGED; COST-BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; ELECTRIC COUNTERSHOCK; FEMALE; HEALTH CARE COSTS; HUMANS; ITALY; MALE; PRIMARY PREVENTION; REGISTRIES;

EID: 33751356548     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2006.00490.x     Document Type: Article

References (32)

1. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001; 104:2158-2163.
2. Josephson M, Wellens HJ. Implantable defibrillators and sudden cardiac death. Circulation 2004;109:2685-2691.
3. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877-883.
4. Boriani G, Biffi M, Martignani C, Camanini C, Grigioni F, Rapezzi C, Branzi A. Cardioverter-defibrillators after MADIT II: The balance between weight of evidence and treatment costs. Eur JHeart Failure 2003; 5:419-425.
5. Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: A pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004; 44:2166-2172.
6. Al-Khatib SM, Sanders GD, Mark DB, et al., Expert panel participating in a Duke Clinical Research Institute-sponsored conference. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: Randomized trial evidence through 2004. Am Heart J 2005; 149:1020-1034.
7. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-237.
8. Capucci A, Boriani G. Drugs, surgery, cardioverter defibrillator: A decision based on the clinical problem. Pacing Clin Electrophysiol 1993; 16:519-526.
9. Camm AJ, Nisam S. The utilization of the implantable defibrillator - A European enigma. Eur Heart J 2000; 21:1998-2004.
10. Capucci A, Aschieri D, Piepoli MF, Bardy GH, Iconomu E, Arvedi M. Tripling survival from sudden cardiac arrest via early defibrillation without traditional education in cardiopulmonary resuscitation. Circulation 2002; 106:1065-1070.
11. Desai AS, Fang JC,Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: A meta-analysis of randomized controlled trials. JAMA 2004; 292:2874-2879.
12. Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: A systematic review of randomized, controlled trials. Ann Intern Med 2003; 138:445-452.
13. Hlatky MA. Evidence-based use of cardiac procedures and devices. N Engl J Med 2004; 350:2126-2128.
14. Pauker SG, Estes NA, Salem DN. Preventing sudden cardiac death: Can we afford the benefit? Ann Intern Med 2005; 142:664-666.
15. Cohen JW, Krauss NA. Spending and service use among people with the fifteen most costly medical conditions, 1997. Health Aff 2003; 22:129-138.
16. Meltzer MI. Introduction to health economics for physicians. Lancet 2001; 358:993-998.
17. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: Part I. Circulation 2002; 106:516-520.
18. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: Part II. Circulation 2002; 106:626-630.
19. Boriani G, Biffi M, Martignani C, Gallina M, Branzi A. Cost-effectiveness of implantable cardioverter-defibrillators. Eur Heart J 2001; 22:990-996.
20. Boriani G, Larsen G. Cost-effectiveness of implantable cardioverter-defibrillators. In: Priori S, Zipes DP (eds.): Sudden Cardiac Death. Malden, Blackwell Publishing, 2006, pp. 263-279.
21. Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, Graham JD. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15:369-390.
22. Lynd LD, O'Brien BJ. Cost-effectiveness of the implantable cardioverter-defibrillator: A review of current evidence. J Cardiovasc Electrophysiol 2003; 14:S99-S103.
23. Hlatky MA, Bigger JT. Cost-effectiveness of the implantable cardioverter defibrillator? Lancet 2001; 357:1817-1818.
24. Mark DB. Cost-effectiveness of ICD therapy in the Sudden Death in Heart Failure Trial (SCD-HeFT). Presented at the Late Breaking Trials session of the Annual Meeting of the American Heart Association, New Orleans, November 10, 2004.
25. Jauhar S, Slotwiner DJ. The economics of ICDs. N Engl JMed 2004; 351:2542-2544.
26. Franciosa JA. The potential role of community-based registries to complement the limited applicability of clinical trial results to the community setting: Heart failure as an example. Am J Manag Care 2004; 10:487-492.
27. Reynolds MR, Josephson ME. MADIT II (second Multicenter Automated Defibrillator Implantation Trial) debate: Risk stratification, costs, and public policy. Circulation 2003; 108:1779-1783.
28. Sweeney MO, Schoenfeld MH, Cannom DS. Rules of evidence: CMS and primary prevention of sudden cardiac death in systolic heart failure. Pacing Clin Electrophysiol 2005; 28:81-88.
29. Chan PS, Hayward RA. Mortality reduction by implantable cardioverter-defibrillators in high-risk patients with heart failure, ischemic heart disease, and new-onset ventricular arrhythmia: An effectiveness study. J Am Coll Cardiol 2005; 45:1474-1481.
30. Tavazzi L. Ventricular pacing: A promising new therapeutic strategy in heart failure. For whom? Eur Heart J 2000; 21:1211-1214.
31. Boriani G, Maron B, Shen WK, Spirito P. Prevention of sudden death in hypertrophic cardiomyopathy: But which defibrillator for which patient? Circulation 2004; 110:e438-e442.
32. Hauser R. The growing mismatch between patient longevity and the service life of implantable cardioverter-defibrillators. J Am Coll Cardiol 2005; 45:2022-2025.